The antimicrobial effect of heparin on common respiratory pathogens

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Inhaled heparin possesses mucolytic, anticoagulative, anti-inflammatory, and neo-angiogenic properties.
• These properties suggest potential benefits for patients with burns and cystic fibrosis.
• The antibacterial potential of unfractionated heparin requires investigation.

Purpose of the Study:

• To assess the antibacterial effects of unfractionated heparin against common respiratory pathogens.
• To determine if unfractionated heparin can inhibit the growth of specific bacterial and fungal isolates.

Main Methods:

• Clinical isolates of Acinetobacter baumannii, Candida albicans, Haemophilus influenzae, Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus pneumoniae were used.
• Bacterial cultures were incubated with varying doses of unfractionated heparin (250-7500 U).
• Colony counts were performed after overnight incubation to assess bacterial viability and growth inhibition.

Main Results:

• Unfractionated heparin demonstrated dose-dependent growth inhibition in three of seven Streptococcus pneumoniae isolates and one of five Haemophilus influenzae isolates.
• Complete inhibition was observed at 2500 U for S. pneumoniae and 7500 U for H. influenzae.
• No significant antibacterial effect was noted against other tested pathogens, including Acinetobacter baumannii, Candida albicans, Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, and Pseudomonas aeruginosa.

Conclusions:

• Unfractionated heparin exhibits unpredictable and limited antibacterial activity against common respiratory pathogens.
• The observed inhibition was strain-specific and dose-dependent, suggesting it is unlikely to be a reliable antibacterial agent.
• Further research is needed to explore alternative applications or formulations of heparin for antimicrobial purposes.